Fibroblast growth factor 7: An inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 2, 2005, Pages 1012-1020

  Carpenter, Thomas O ^a   Ellis, Bruce K ^a   Insogna, Karl L ^a   Philbrick, William M ^a   Sterpka, John ^a   Shimkets, Richard ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CURAGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIPHYSIN; CATHEPSIN B; CD4 ANTIGEN; KERATINOCYTE GROWTH FACTOR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OSTEOPROTEGERIN; PHOSPHATE; RNA; SOMATOMEDIN BINDING PROTEIN 5;

ADULT; ARTICLE; CASE REPORT; CHILD; CONTROLLED STUDY; DNA SYNTHESIS; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOASSAY; KIDNEY TUBULE EPITHELIUM; MALE; NUCLEOTIDE SEQUENCE; ONCOGENIC OSTEOMALACIA; OSTEOMALACIA; PHOSPHATE TRANSPORT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR CELL;

ADULT; ANTIGENS, CD4; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; CULTURE MEDIA, CONDITIONED; FIBROBLAST GROWTH FACTOR 7; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; KINETICS; MALE; MIDDLE AGED; OSTEOMALACIA; PHOSPHATE TRANSPORT PROTEINS;

EID: 14044267649     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-0357     Document Type: Article

References (31)

1. Calvo M, Carpenter TO 2003 Influence of phosphorus on bone health. In: New SA, Bonjour J-P, eds. Nutritional aspects of bone health. Cambridge, UK: Royal Society of Chemistry; 229-265
2. Tenenhouse HS, Murer H 2003 Disorders of renal tubular phosphate transport. J Am Soc Nephrol 14:240-248
3. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505
4. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2004 FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Research Commun 314:409-414
5. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561-568
6. i collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087-3094
7. Jonsson KB, Zahradnik R, Larsson T, White K, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663
8. Nelson AE, Bligh RC, Mirams M, Gill A, Au A, Clarkson A, Jüppner H, Ruff S, Stalley P, Scolyer RA, Robinson BG, Mason RS, Bligh PC 2003 Clinical case seminar: fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab 88:4088-4094
9. Weber TJ, Liu S, Indridason OS, Quarles LD 2003 Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227-1234
10. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC 2001 FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284:977-981
11. Carpenter TO 2003 Oncogenic osteomalacia: a complex dance of factors. N Engl J Med 348:1705-1708
12. Reyes-Mugica M, Arnsmeier SL, Backeljauw PF, Persing J, Ellis B, Carpenter TO 2000 Phosphaturic mesenchymal tumor-induced rickets. Pediatr Dev Pathol 3:61-69
13. Biber J, Malmstrom K, Reshkin S, Murer H 1990 Phosphate transport in established renal epithelial cell lines. Methods Enzymol 191:494-505
14. Bell CL, Tenenhouse HS, Scriver CR 1988 Primary cultures of renal epithelial cells from X-linked hypophosphatemic (Hyp) mice express defects in phosphate transport and vitamin D metabolism. Am J Hum Genet 43:293-303
15. Shimkets RA, Lowe DG, Tai JT, Sehl P, Jin H, Yang R, Predki PF, Rothberg BEG, Murtha MT, Roth ME, Shenoy SG, Windemuth A, Simpson JW, Simons JF, Daley MP, Gold SA, McKenna MP, Hillan K, Went GT, Rolhberg JM 1999 Gene expression analysis by transcript profiling coupled to a gene database query. Nat Biotechnol 17:798-803
16. HYP Consortium 1995 A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130-136
17. Quarles LD 2003 FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol 285:E1-E9
18. ADHR Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348
19. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ 2001 Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079-2086
20. Bai XY, Miao D, Goltzman D, Karaplis AC 2003 The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843-9849
21. Jan De Beur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, Manavalan P, Petroziello J, Madden S, Cho JY, Kumar R, Levine MA, Schiavi SC 2002 Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17:1102-1110
22. Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De Beur SM, Schiavi SC, Kumar R 2003 Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112:785-794
23. Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA 2003 Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278:1998-2007
24. Rowe PSN, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR 2004 MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303-319
25. Beer HD, Gassmann MG, Munz B, Steiling H, Engelhardt F, Bleuel L, Werner S 2000 Expression and function of keratinocyte growth factor and activin in skin morphogenesis and cutaneous wound repair. J Invest Dermatol Symp Proc 5:34-39
26. Danilenko DM 1999 Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol 27:64-71
27. MacDonald TT, Monteleone G, Pender SL 2000 Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 51:2-9
28. Lamerz R 1999 Role of tumour markers, cytogenetics. Ann Oncol 10(Suppl 4):145-149
29. Ornitz DM, Marie PJ 2002 FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16:1446-1465
30. Yamashita T, Konishi M, Miyake A, Inui K, Itoh N 2002 Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 277:28265-28270
31. White KE, Cabral JM, Evans WE, Ichikawa S, Davis SI, Econs MJ 2003 A missense mutation in FGFR1 causes a novel syndrome: craniofacial dysplasia with hypophosphatemia (CFDH). J Bone Miner Res 18(Suppl 2):S4